Page 8 - Johnc Jacobs News Today

The University of Oxford-developed and Serum Institute of India PvT Ltd (SIIPL)- manufactured and scaled up R21/Matrix-MTM malaria vaccine, leveraging Novavax’s adjuvant technology, has been licensed for use in Ghana by the country’s Food and Drugs Authority The R21/Matrix-M™ malaria vaccine, developed by the University of Oxford, leveraging an adjuvant…

A University of Oxford developed and Serum Institute of India (SII) manufactured and scaled up "high efficacy" malaria vaccine has been licensed for use in Ghana by Africa's Food and Drugs Authority, the university announced here on Thursday.

The vaccine maker gave a warning that no investor wants to hear.

/PRNewswire/ -- The Coronavirus Global Market has been growing in the past few years and is anticipated to continue to grow in the next several years. In fact,...

Achieved revenues in fourth quarter 2022 of $357 million and full year 2022 of $2.0 billion Appointed John C. Jacobs as President and Chief Executive Officer...

GAITHERSBURG, Md., Feb. 13, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing

/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious...

Novavax stock sank 92% last year.

Deeply embattled biotechnology specialist Novavax (NASDAQ:NVAX) popped dramatically higher on Monday, closing up 11.25% against the Friday session.

Leqembi’s manufacturers estimate the drug will be available by Jan. 23 and have priced the biweekly infusion at $26,500 annually.